Facebook Linkedin RSS Twitter Youtube
Home 2024

Novartis

Novartis, PTC Ink Up-to-$2.9B Huntington’s Disease Collaboration
Drug Discovery

Novartis, PTC Ink Up-to-$2.9B Huntington’s Disease Collaboration

Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy
Drug Discovery

Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy

Schrödinger, Novartis Ink Up-to-$2.3B Collaboration, Software Agreement
Drug Discovery

Schrödinger, Novartis Ink Up-to-$2.3B Collaboration, Software Agreement

Novartis, Monte Rosa Launch Up-to-$2.1B Molecular Glue Collaboration
Drug Discovery

Novartis, Monte Rosa Launch Up-to-$2.1B Molecular Glue Collaboration

Roche, Dyno Launch $1B+ AAV Gene Therapy Vector Collaboration
Genome Editing

Roche, Dyno Launch $1B+ AAV Gene Therapy Vector Collaboration

Novartis, Generate:Biomedicines Sign Up-to-$1B AI Protein Drug Collaboration
Artificial Intelligence

Novartis, Generate:Biomedicines Sign Up-to-$1B AI Protein Drug Collaboration

Cardurion Builds Cardiovascular Pipeline with $260M Series B Financing
Drug Discovery

Cardurion Builds Cardiovascular Pipeline with $260M Series B Financing

Gee WIZ: Novartis’ “Glue Degrader” Drug Candidate for Sickle Cell Shows Promise in Animal Studies
GEN Edge

Gee WIZ: Novartis’ “Glue Degrader” Drug Candidate for Sickle Cell Shows Promise in Animal Studies

Bertozzi’s TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle
Cancer

Bertozzi’s TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle

JAK Attack: Ajax Takes Aim at Myelofibrosis
Cancer

JAK Attack: Ajax Takes Aim at Myelofibrosis

123...56Page 1 of 56
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.